학술논문
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia.
Document Type
Article
Author
Source
Subject
*THYROIDITIS
*PURE red cell aplasia
*CHRONIC inflammatory demyelinating polyradiculoneuropathy
*THROMBOCYTOPENIA
*REGULATORY T cells
*
*
*
*
Language
ISSN
0007-1048
Abstract
Patients with AAT are often initially misdiagnosed as having immune thrombocytopenia (ITP) but do not usually respond to ITP first-line therapy (i.e. corticosteroids [CS] and intravenous immunoglobulin [IVIg]). After a median follow-up of 4.0 years (range: 1.2-11.9), two (16.7%) patients developed AA (7 and 41.5 months after AAT diagnosis), and two developed B-cell lymphoma (8 and 9 years after AAT diagnosis). Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Amegakaryocytic thrombocytopenia is characterized by severe thrombocytopenia associated with aplastic or hypoplastic megakaryocytic lineage in the bone marrow (BM), and usually preserved granular and erythroid lineage. [Extracted from the article]